查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620662

藥物基因體學市場：按產品、技術、適應症和應用分類 - 2025-2030 年全球預測

Pharmacogenomics Market by Product (Consumables, Kits & Reagents, Services), Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥物基因體學市場價值為40.6億美元，預計到2024年將達到44.8億美元，複合年成長率為10.54%，到2030年將達到82億美元。

藥物基因體學是研究基因如何影響人的藥物反應，透過根據個人的基因組成客製化治療策略，提供更個人化的醫學方法。該領域對於推進精準醫學、最大限度地減少副作用和提高藥物療效至關重要。藥物基因體學學應用涵蓋腫瘤學、循環系統、神經病學和感染疾病等多個領域，並被製藥、診斷和個人化醫療公司使用。最終用途範圍包括希望實施或增強精準醫療能力的醫院、研究機構和生物製藥公司。

主要市場統計
基準年[2023] 40.6億美元
預計年份 [2024] 44.8億美元
預測年份 [2030] 82億美元
複合年成長率（%） 10.54%

由於對個人化醫療的需求不斷成長、不利事件的增加以及基因組定序技術的進步，藥物基因體學市場正在不斷成長。人工智慧和巨量資料分析的整合帶來了巨大的潛在機遇，監管機構對基於藥物基因體學的藥物的核准也越來越多。為了充分利用這些前景，鼓勵相關人員專注於研發，與基因組技術公司合作，並對醫療保健專業人員進行藥物基因組學測試的好處和應用的教育。

然而，市場面臨基因檢測成本上升、對基因隱私的倫理擔憂以及新興市場缺乏意識和基礎設施等挑戰。監管障礙和不良的報銷框架也阻礙了市場的成長。

創新和研究的關鍵領域包括開發更具成本效益的定序技術、增強資料解釋軟體以及擴大臨床試驗以提供基於證據的基因藥物交互作用的見解。該市場充滿活力但又分散，由於支持性政策和成熟的醫療保健系統，新興經濟體具有強勁的成長潛力。對於尋求在藥物基因體學領域取得進步的相關人員來說，有效應對現有挑戰並利用最尖端科技至關重要。

市場動態：揭示快速發展的藥物基因體學市場的關鍵市場洞察

供需的動態交互作用正在改變藥物基因體學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病增加和精準醫療需求不斷成長
    • 加大醫療基礎建設投資
    • 分子診斷相關技術的進步
  • 市場限制因素
    • 與研發相關的高成本
  • 市場機會
    • 個人化醫療和消費者基因檢測服務的成長趨勢
    • 增加對研發活動的投資以改善藥物基因體學
  • 市場挑戰
    • 缺乏意識和所需的基礎設施

波特五力：駕馭藥物基因體學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解藥物基因體學市場的外部影響

外部宏觀環境因素在塑造藥物基因體學市場的動態表現方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解藥物基因體學市場的競爭格局

藥物基因體學市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位藥物基因體學市場供應商的績效評估

FPNV定位矩陣是評估藥物基因體學市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製藥物基因體學市場的成功之路

藥物基因體學市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病發生率上升和精準醫療需求
      • 加大醫療基礎建設投資
      • 與分子診斷程序相關的技術進步
    • 抑制因素
      • 與研發能力相關的高成本
    • 機會
      • 個人化醫療和消費者基因檢測服務的新興趨勢
      • 增加對研發活動的投資以改善藥物基因體學
    • 任務
      • 缺乏意識和必要的基礎設施
  • 市場區隔分析
    • 技術：聚合酵素鏈鎖反應技術的進步
    • 應用：藥物基因體學在各行業的多樣化應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章藥物基因體學市場：依產品

  • 消耗品
  • 試劑套件和試劑
  • 服務

第7章藥物基因體學市場：依技術分類

  • DNA序列分析
  • 電泳
  • 質譜分析
  • 微陣列
  • 聚合酵素鏈鎖反應

第8章藥物基因體學市場（按適應症）

  • 神經病學
  • 腫瘤學
  • 疼痛管理

第9章藥物基因體學市場：依應用分類

  • 臨床診斷實驗室
  • 臨床研究和藥物發現
  • 個人化醫療

第10章美洲藥物基因體學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物基因體學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的藥物基因體學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • SOPHiA GENETICS 宣布擴大與 CHU de Nimes 的業務
    • Diatech Pharmaco Genetics 宣佈建立新的合作夥伴關係，以推進腫瘤學的精確測試
    • MyRx 開始提供虛擬藥物基因檢測諮詢
  • 戰略分析和建議

公司名單

  • Admera Health
  • Agena Biosciences Inc. by Mesa Laboratories, Inc.
  • BiogeniQ Inc.
  • Castle Biosciences, Inc.
  • CENTOGENE NV
  • Coriell Life Sciences
  • Diatech Pharmacogenetics
  • Dynamic DNA Laboratorie
  • Empire Genomics by Biocare Medical
  • Exceltox Laboratories
  • Genelex Corporation by Invitae
  • Genetworx
  • Genomind
  • GenXys
  • Gravity Diagnostics
  • Illunima Inc.
  • Integra Laboratories
  • Kailos Genetics by healthOme
  • Myriad Genetics Inc.
  • OneOme LLC
  • Personalis Inc.
  • Phamatech Inc. by Caris Life Sciences
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • ViennaLab Diagnostics GmbH by BioVendor Group
Product Code: MRR-742BD5183871

The Pharmacogenomics Market was valued at USD 4.06 billion in 2023, expected to reach USD 4.48 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 8.20 billion by 2030.

Pharmacogenomics is the study of how genes affect a person's response to drugs, offering a more personalized medicine approach by tailoring therapeutic strategies to individuals' genetic make-ups. This field is essential in advancing precision medicine, minimizing adverse drug reactions, and improving drug efficacy. The application of pharmacogenomics spans various areas including oncology, cardiology, neurology, and infectious diseases, and is utilized by pharmaceuticals, diagnostics, and personalized medicine companies. The end-use scope involves hospitals, research institutions, and biopharmaceutical companies seeking to implement or enhance precision medicine capabilities.

KEY MARKET STATISTICS
Base Year [2023] USD 4.06 billion
Estimated Year [2024] USD 4.48 billion
Forecast Year [2030] USD 8.20 billion
CAGR (%) 10.54%

The market for pharmacogenomics is growing due to personalized medicine's increasing necessity, rising adverse drug events, and technological advancements in genomic sequencing. The integration of artificial intelligence and big data analytics presents significant potential opportunities, as does the increasing approval of pharmacogenomic-informed drugs by regulatory bodies. To capitalize on these prospects, stakeholders are recommended to invest in R&D, collaborate with genomic technology firms, and focus on educating healthcare professionals about the benefits and applications of pharmacogenomic testing.

However, the market faces challenges such as high costs of genetic testing, ethical concerns regarding genetic privacy, and a lack of widespread awareness and infrastructure in developing regions. Regulatory hurdles and scarce reimbursement frameworks also impede market growth.

Key areas for innovation and research include developing more cost-effective sequencing technologies, enhancing data interpretation software, and expanding clinical trials to provide evidence-driven insights into gene-drug interactions. The market is dynamic yet fragmented, with significant potential for growth in developed economies due to supportive policies and established healthcare systems. Efficiently addressing the existing challenges and leveraging cutting-edge technologies will be crucial for stakeholders aiming to advance in the pharmacogenomics field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacogenomics Market

The Pharmacogenomics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic diseases and demand for precision medicine
    • Increasing investments for healthcare infrastructures
    • Technological advancements associated with molecular diagnostics procedure
  • Market Restraints
    • High costs associated with research and development proficiencies
  • Market Opportunities
    • Emerging trend of personalized medicines and direct-to-consumer genetic testing services
    • Rising investment in R&D activities to improve pharmacogenomics
  • Market Challenges
    • Dearth of awareness and required infrastructural facilities

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacogenomics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacogenomics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacogenomics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacogenomics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacogenomics Market

A detailed market share analysis in the Pharmacogenomics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacogenomics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacogenomics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmacogenomics Market

A strategic analysis of the Pharmacogenomics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc. by Mesa Laboratories, Inc., BiogeniQ Inc., Castle Biosciences, Inc., CENTOGENE N.V., Coriell Life Sciences, Diatech Pharmacogenetics, Dynamic DNA Laboratorie, Empire Genomics by Biocare Medical, Exceltox Laboratories, Genelex Corporation by Invitae, Genetworx, Genomind, GenXys, Gravity Diagnostics, Illunima Inc., Integra Laboratories, Kailos Genetics by healthOme, Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc. by Caris Life Sciences, Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH by BioVendor Group.

Market Segmentation & Coverage

This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Kits & Reagents, and Services.
  • Based on Technology, market is studied across DNA Sequencing, Electrophoresis, Mass Spectrometry, Microarray, and Polymerase Chain Reaction.
  • Based on Indication, market is studied across Neurology, Oncology, and Pain Management.
  • Based on Application, market is studied across Clinical Diagnostics Labs, Clinical Research & Drug Discovery, and Personalized Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
      • 5.1.1.2. Increasing investments for healthcare infrastructures
      • 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development proficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of personalized medicines and direct-to-consumer genetic testing services
      • 5.1.3.2. Rising investment in R&D activities to improve pharmacogenomics
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of awareness and required infrastructural facilities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advances in Polymerase Chain Reaction technique
    • 5.2.2. Application: Diverse applications of pharmacogenomics across industries
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacogenomics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Kits & Reagents
  • 6.4. Services

7. Pharmacogenomics Market, by Technology

  • 7.1. Introduction
  • 7.2. DNA Sequencing
  • 7.3. Electrophoresis
  • 7.4. Mass Spectrometry
  • 7.5. Microarray
  • 7.6. Polymerase Chain Reaction

8. Pharmacogenomics Market, by Indication

  • 8.1. Introduction
  • 8.2. Neurology
  • 8.3. Oncology
  • 8.4. Pain Management

9. Pharmacogenomics Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics Labs
  • 9.3. Clinical Research & Drug Discovery
  • 9.4. Personalized Medicine

10. Americas Pharmacogenomics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacogenomics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacogenomics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. SOPHiA GENETICS Announces Expansion of Work with CHU de Nimes
    • 13.3.2. Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology
    • 13.3.3. MyRx launches to provide virtual pharmacogenetic testing consultations
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Admera Health
  • 2. Agena Biosciences Inc. by Mesa Laboratories, Inc.
  • 3. BiogeniQ Inc.
  • 4. Castle Biosciences, Inc.
  • 5. CENTOGENE N.V.
  • 6. Coriell Life Sciences
  • 7. Diatech Pharmacogenetics
  • 8. Dynamic DNA Laboratorie
  • 9. Empire Genomics by Biocare Medical
  • 10. Exceltox Laboratories
  • 11. Genelex Corporation by Invitae
  • 12. Genetworx
  • 13. Genomind
  • 14. GenXys
  • 15. Gravity Diagnostics
  • 16. Illunima Inc.
  • 17. Integra Laboratories
  • 18. Kailos Genetics by healthOme
  • 19. Myriad Genetics Inc.
  • 20. OneOme LLC
  • 21. Personalis Inc.
  • 22. Phamatech Inc. by Caris Life Sciences
  • 23. Quest Diagnostics
  • 24. Thermo Fisher Scientific Inc.
  • 25. ViennaLab Diagnostics GmbH by BioVendor Group

LIST OF FIGURES

  • FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOGENOMICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL RESEARCH & DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023